뉴스센터 >
주요 읽을거리
보도자료
12월 07, 2020
United States
Data from the ANDROMEDA Study Show Hematologic Response for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Newly Diagnosed Light Chain (AL) Amyloidosis
12월 07, 2020
United States
New DARZALEX® (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma
12월 06, 2020
United States
New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
12월 05, 2020
United States
Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
트윗
Janssen Global
@JanssenGlobal
-
Jennifer is on a “mission to spread awareness of #PH to those living with PH and to other young people” Watch Jenni… https://t.co/LHCPKbDG7E
10 hours 32 min ago

닫기